Rosen et al
1 present diffuse interstitial haemorrhage as the main manifestation of cyclophosphamide-induced cardiomyopathy. A careful analysis of their Figure 1a shows, however, that a great many of the alleged red cells are not situated in the interstitial space but inside clearly recognizable hypereosinophilic (orange color) cardiomyocytes. This picture may be explained only by the hypothesis that numerous hypereosinophilic cardiomyocytes have fragmented into apoptotic bodies similar to red cells 2 which are subsequently perceived in the interstitial space.
The above observation is corroborated by the findings of other authors who also considered interstitial haemorrhage to be the main feature of cyclophosphamide-induced cardiomyopathy. [3] [4] [5] Note that the haemorrhagic sites described in Figures 7,  3 13 4 and 6 5 do not exercise any pressure on the surrounding myocardium and that they do not push cardiomyocytes from their positions in the normal myocardium, suggesting that the alleged red cells are located in the places occupied previously by cardiomyocytes and that they may be, in reality, cardiomyocyte apoptotic bodies.
This proposition is supported by the following facts: (1) the alleged red cells are often located inside recognizable cardiomyocytes or inside their empty sarcolemmal-endomysial tubes (Figure 7 in the upper left corner), (4) myocytolysis, one of the in vivo manifestations of apoptosis, 6 is a feature of cyclophosphamide-induced cardiomyopathy (Figure 4 ), 4 and (5) the alleged haemorrhage does not contain platelet and fibrin strands (Figure 7   4 ). In writing this, I do not intend to refute well-known myocardial microvascular pathologic changes provoked by cyclophosphamide and, consequently, a possible egress of some red cells into the interstitial space. The purpose of my letter is to focus attention toward pathologic phenomena which are incompatible with interstitial haemorrhage and which have escaped the attention of the investigators, such as the disappearance of non-necrotic cardiomyocytes. Perhaps an appropriate antiapoptotic treatment (cyclosporin A?) 7 given with cyclophosphamide will diminish the clinical cardiotoxicity of this important drug.
JT Beranek
4101 South Wappel Drive Columbia, MO 65203, USA
